Connect your AI

Celldex Therapeutics CLDX Total Equity

Total Equity at other companies

Eli LillyLLY

$31.2B+97.9%

PfizerPFE

$90.1B-0.3%

Rogers CorporationROG

$1.19B-6.1%

AmgenAMGN

$9.19B+48.1%

Regeneron PharmaceuticalsREGN

$31.42B+6.9%

IncyteINCY

$5.62B+53.3%

Other financials

Income statement

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total assets$511.3M-30.9%

Cash flow

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Celldex Therapeutics's total equity?: Celldex Therapeutics (CLDX) reported total equity of $456.23M in Q1 2026.
How has Celldex Therapeutics's total equity changed year-over-year?: Celldex Therapeutics's total equity decreased by 35.1% year-over-year, from $702.98M to $456.23M.
What is the long-term trend for Celldex Therapeutics's total equity?: Over 5 years (2020 to 2025), Celldex Therapeutics's total equity has grown at a 20.3% compound annual growth rate (CAGR), from $209.36M to $527.17M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.